Elan: Nanotech Investors Keep Your Eye on the Prize
On March 2, after Elan dropped 70 percent in one day, I encouraged nanotech investors that it was a good time to look at Elan for its NanoCrystal technology. Today, after the company’s stock dropped another 50 percent, I still believe the company’s NanoCrystal technology—while not yet a substantial portion of the company’s revenues—offers substantial long term promise. (Full disclosure: I own Elan stock).
While it is clear that Tysabri will now represent a significantly smaller share of the company’s overall future revenues, the company still has some other attractive products in its pipeline.
As I said on March 2—and I repeat now--do your own due diligence … but that’s my two cents.
Related Links:
Nano-based Drug Delivery
Starpharma "Nano" star on the rise?
Elan Good News for Nanotech Investors?
pSivida: Down Under Comapny has Big Upside Potential
While it is clear that Tysabri will now represent a significantly smaller share of the company’s overall future revenues, the company still has some other attractive products in its pipeline.
As I said on March 2—and I repeat now--do your own due diligence … but that’s my two cents.
Related Links:
Nano-based Drug Delivery
Starpharma "Nano" star on the rise?
Elan Good News for Nanotech Investors?
pSivida: Down Under Comapny has Big Upside Potential